An interventional study of Peer support and Exercise Prescription in HIV and Hypertension, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.
Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 22nd largest by enrollment of the 38 interventional ones that give a count, is one of 7 that started in 2026, is one of 29 with no phase, and was the 37th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 60+
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18–55
University of Alabama at Birmingham · Sites in United States
Ages 18–89
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 71 across the 38 interventional studies, 378 across the 6 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
2 of the studies in Hypertension by University of Alabama at Birmingham that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT07760350University of Alabama at BirminghamAssessing the Feasibility of the "Heart Care Pairs" Intervention | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Hypertension by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will assess the acceptability and feasibility of a peer-supported behavioral physical activity intervention for women living with HIV and Hypertension.
An individually randomized pilot trial (N=50) of an adapted behavioral physical activity (PA) intervention will be used to assess the feasibility and acceptability of providing exercise prescription, peer support, and home blood pressure monitoring to women ages 40+ living with HIV and Hypertension. Secondary outcomes to be assessed include systolic and diastolic blood pressure, PA time and intensity, PA self-efficacy, perceived social support, and health-related quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women in the peer support arm will receive weekly peer contacts via phone or text message to assess progress towards study-assigned physical activity goal/prescription and to provide motivational counseling and support.
Behavioral: Peer support · Behavioral: Exercise Prescription · Behavioral: Blood pressure self monitoring
Women in the control arm will receive physical activity prescription and home blood pressure monitoring, but will not receive peer support calls.
Behavioral: Exercise Prescription · Behavioral: Blood pressure self monitoring
Peer support counseling will include phone or text communication to assess goal progress, provide motivational counseling as needed, and to provide social support.
Women will be provided with an exercise prescription (Frequency, Intensity, Time, Type) which may be adjusted weekly for 6 weeks to goal of 150min/week of moderate to vigorous physical activity.
Women will receive a home blood pressure monitor and encourage to record their readings in a log.
Participant attrition
Measure of participants who withdraw from the behavioral trial in the intervention and the control groups to determine feasibility of enrolling and retaining individuals in the trial. Approximately 15% attrition is expected in a behavioral clinical trial. Higher levels of attrition relate to lower feasibility.
Time frame: From enrollment to end of 12 week intervention
Intervention acceptability: Satisfaction
Participant satisfaction with the intervention: Treatment Satisfaction Questionnaire adapted for behavioral treatment. The measure includes 11 items asked on a Likert-type scale from 1=Extremely Dissatisfied to 7=Extremely Satisfied, with 3 items asked on a 1-5 scale. 1 item will be removed that asks about medication side effects. Scores can range from 10 to 64. Higher scores mean higher satisfaction with the treatment/intervention.
Time frame: Mid-point (6-week) assessment and end of intervention assessment (12-week)
Intervention Acceptability: Treatment burden
The Brief Patient Experiences with Treatment and Self Management will be used. The scale includes 32 items total. Most items use a 5-point Likert-type scale from 1=very easy to 5=very difficult. Some items use a 5-point Likert scale (agreement). And some use a Likert-type frequency/intensity measure from 1=not at all to 5=very much. Does not apply=0. Total scores range from 0 to 150. Higher scores mean higher treatment burden.
Time frame: At 6-week (mid-point intervention) and 12-weeks (end of intervention)
Systolic and diastolic blood pressure
Home blood pressure readings taken x3 and averaged.
Time frame: Measured at baseline, 6-weeks (mid-point) and 12-weeks (end of intervention)
Daily physical activity: Accelerometer measured
7-day accelerometer observation of daily physical activity
Time frame: Collected at baseline pre-randomization, and at 12-weeks (end of intervention)
Self reported physical activity
Time and intensity of physical activity via the International Physical Activity Questionnaire - Short Form (IPAQ-SF) which are then computed to a continuous score of MET (metabolic equivalents)-minutes per week. Computed as follows: Total PA METmin/week=\[(3.3\*walking minutes\*walking days)+(4.0\*moderate activity minutes\*moderate activity days)+(8.0\*vigorous activity minutes\*vigorous activity days)\]. Higher scores mean greater physical activity.
Time frame: Collected at baseline, 6 weeks (mid-point), and 12-weeks (post-intervention)
Physical Activity Self Efficacy
Confidence to engage in regular physical activity will be measured using the Exercise Self Efficacy Scale. A total of 9 items are asked using a scale from 0=not at all confident to 10=completely confident. Scores range from 0-90. Higher scores mean higher self efficacy.
Time frame: Collected at baseline, 6-weeks (mid-point) and 12-weeks (post-intervention)
Physical activity enjoyment
Physical activity enjoyment scale will be used. The scale has 18 items and each item is asked on a 1 to 7 scale. Scores may range from 18-126. Higher scores mean higher enjoyment and perceived positive outcomes from exercise/physical activity.
Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)
Social support for physical activity
Social support for exercise behaviors scale will be used that includes 10 items asked on a scale from 1=none to 5=very often, there is also an option for does not apply. Scores range from 10-50. Higher scores mean more social support for physical activity.
Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)
General Social Support
Medical outcomes study social support scale will be used to assess global social support. The scale includes 19 items and the overall support index is calculated by taking the mean of all of the items resulting in a range from 1-5. Scores can be transformed to a 0-100 score by the following equation: 100\*((observed score-minimum possible score)/(maximum possible score-minimum possible score)). Higher scores mean greater social support.
Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)
Health related quality of life
The Short Form Health Survey-12 (SF-12) will be used to assess Health related quality of life (HRQoL) which asks about physical and emotional health in the past 4 weeks using 12 items. In scoring, all items are coded to yield a total score between 0 and 100 such that higher scores mean better HRQoL.
Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)
Plan to share: No — Pilot trial; Certificate of confidentiality
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Aug 2026, 6 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →